CM
IDYA icon

Crestline Management’s IDEAYA Biosciences IDYA Stock Holding History

Crestline Management’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-95,428
Closed -$2.45M – 304
2024
Q4 		$2.45M Buy
95,428
+70,571
+284% +$2M 0.08% 248
2024
Q3 		$787K Buy
+24,857
New +$943K 0.04% 300

Other funds holding IDYA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Crestline Management's IDYA Position: Q1 2025 in Review

Crestline Management sold out of IDEAYA Biosciences (IDYA) in Q1 2025, closing a stake of 95,428 shares — an estimated $2.45M sold.

Crestline Management first reported a position in IDYA in Q3 2024 and held it in 2 quarters. The position peaked at $2.45M in Q4 2024. 207 funds tracked by Wall St. Rank hold IDYA as of Q1 2025.

  • Crestline Management reported no remaining IDEAYA Biosciences position as of Q1 2025 after selling out during the quarter.
  • Crestline Management sold 95,428 IDEAYA Biosciences shares in Q1 2025, an estimated $2.45M.
  • Crestline Management first reported a position in IDEAYA Biosciences in Q3 2024 and held it in 2 quarters.
  • Crestline Management's IDEAYA Biosciences position peaked at $2.45M in Q4 2024.
  • 207 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.